BeiGene Provides Updates of Tislelizumab in P-III (RATIONALE-309) Trial as 1L Treatment of Recurrent or Metastatic Nasopharyngeal Cancer Presented at ASCO 2022
- The P-III (RATIONALE-309) trial evaluates tislelizumab (200mg) + CT vs CT + PBO in 263 patients with RM-NPC
- The results showed an improvement in PFS at a median follow-up of 15.5mos., m-PFS (9.6mos. vs 7.4mos.) while m-PFS2 (not reached vs 13.9mos.), positive OS trend was observed with m-OS (not reached vs 23mos.) & benefit across other survival EPs. The safety profile was manageable & consistent with the known risks profile
- The biomarker analyses for exploratory EPs including PD-L1 & GEP showed an improvement in PFS regardless of PD-L1 status, PFS benefit in patients exhibiting ‘hot’ tumor microenvironment profiles. The company continues to support the regulatory filings for NPC in the US & EU
Ref: Businesswire | Image: BeiGene
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].